Dare Bioscience, Inc.
Summary
Dare Bioscience, Inc. filed a Form D on 2026-06-02, raising $65.0M in a private placement backed by Flagship Pioneering and ARCH Venture Partners. The first sale date was 2026-06-01, indicating the capital is already deployed. This is a significant raise for a private company in the Technology Venture sector.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Full Analysis
Executive Summary
Dare Bioscience, Inc. filed a Form D on 2026-06-02, raising $65.0M in a private placement backed by Flagship Pioneering and ARCH Venture Partners. The first sale date was 2026-06-01, indicating the capital is already deployed. This is a significant raise for a private company in the Technology Venture sector.
Investor Edge
Watch for a subsequent Form D/A amendment, which would indicate additional capital or changed terms, signaling strong demand or a pivot in strategy. Also monitor for any public announcements from Dare Bioscience regarding partnerships or regulatory milestones.
Sector capital positioning
This $65M raise signals strong institutional appetite for high-risk, high-reward technology ventures, particularly those with ties to top-tier life science venture firms.
Convergence Signals
No direct public signals are evident from the filing data. However, the involvement of Flagship Pioneering and ARCH Venture Partners suggests potential connections to novel platform technologies or therapeutic assets that may have patent filings or upcoming clinical milestones.
Key Takeaways
- Dare Bioscience raised $65.0M in a private placement with first sale on 2026-06-01.
- Backed by elite venture firms Flagship Pioneering and ARCH Venture Partners.
- No public ticker; this is a private company filing a Regulation D notice.
Risk Indicators & Flags
No red flags in this initial Form D filing. The amount is large but consistent with the backing of top-tier VCs. No D/A amendments yet. Sector is Technology Venture, which is broad; specific risk depends on the company's actual product or service, which is not disclosed in the filing.
Verification & References
Filing is a Form D (initial notice) with SEC accession 000149315226026666. Verified via SEC EDGAR at https://www.sec.gov/cgi-bin/browse-edgar?company=DEFA14A%20-%20Dare%20Bioscience%2C%20Inc.%20(0001401914)%20(Filer)&type=D&action=getcompany. Amount raised is $65.0M. Related persons include Flagship Pioneering and ARCH Venture Partners.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Matthias Therapeutics, LLC
Uniform Bio Inc.
Anika Therapeutics, Inc.
DEF 14A - Outlook Therapeutics, Inc.
Strategy Inc
Outlook Therapeutics, Inc.
Pacira BioSciences, Inc.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Declaring a National Emergency to Secure the United States Bulk-Power System
This executive order declares a national emergency to restrict foreign-produced bulk-power system electric equipment that poses national security risks, prohibiting new transactions involving equipment from covered foreign entities and allowing the Secretary of Energy to impose conditions on existing equipment. It directs the Secretary of Energy, in coordination with multiple agencies, to identify, mitigate, and potentially replace risky equipment, and establishes a pre-qualification list for approved vendors.
The National Space Transportation Policy
This memorandum directs multiple agencies to expand and modernize U.S. space launch and reentry infrastructure to support over 1,000 launches annually by 2030, expedite permitting and environmental reviews, develop new federal reentry sites, and strengthen the space transportation industrial base. It mandates range scheduling transparency, spectrum reliability, and workforce development, with specific reports and plans due within 90 to 240 days.
Adjusting Imports of Unmanned Aircraft Systems and Unmanned Aircraft Systems Components into the United States
This proclamation imposes a 100% ad valorem tariff on imports of unmanned aircraft systems (UAS) over 25 kg, those with thermal imagers, docking stations, and certain components, and a 25% tariff on UAS under 25 kg and other components, citing national security under Section 232 of the Trade Expansion Act. It also authorizes the Department of Commerce to establish an onshoring program offering preferential tariff treatment for companies that build new U.S. manufacturing facilities for UAS and components.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →